Tipiracil
Tipiracil Basic information
- Product Name:
- Tipiracil
- Synonyms:
-
- Tipiracil
- Tipiracil (hydrochloride)
- 2,4(1H,3H)-PyriMidinedione,5-chloro-6-[(2-iMino-1-pyrrolidinyl)Methyl] hydrochloride
- 5-Chloro-6-[(2-imino-1-pyrrolidinyl)methyl]-2,4(1H,3H)-pyrimidinedione monohydrochloride
- Tipiracil HCl
- 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]-1H-pyrimidine-2,4-dione,hydrochloride
- 5-Chloro-6-(2-iminopyrrolidin-1-ylmethyl)-1,2,3,4-tetrahydropyrimidine-2,4-dione hydrochloride
- 5-Chloro-6-(2-iminopyrrolidin-1-ylmethyl)uracil hydrochloride
- CAS:
- 183204-72-0
- MF:
- C9H12Cl2N4O2
- MW:
- 279.12318
- Product Categories:
-
- Inhibitors
- API
- Mol File:
- 183204-72-0.mol
Tipiracil Chemical Properties
- Melting point:
- 245℃ (decomposition)
- storage temp.
- 2-8°C
- solubility
- DMSO (Slightly, Heated), Water (Slightly)
- form
- powder
- color
- white to beige
- Stability:
- Hygroscopic
Tipiracil Usage And Synthesis
Description
Tipiracil (TPI) is a potent and competitive inhibitor of thymidine phosphorylase (TPase) with an IC50 value of 35 nM for human placental TPase. It is selective for TPase over other pyrimidine-metabolizing enzymes (IC50s = >1 mM for UPase, OPRTase, TK, and DPDase). TPI inhibits the phosphorolysis and degradation of trifluorothymidine , a cytotoxic nucleoside, in human breast and colon carcinoma tumor samples. Oral administration of TPI (12.5-50 mg/kg) enhances the anti-tumor activity of trifluorothymidine in a mouse AZ-521 stomach cancer xenograft model. Formulations containing TPI have been used for the treatment of metastatic colorectal cancer.
Uses
Tipiracil Hydrochloride serves as a treatment for metastatic colorectal cancer (mCRC). A thymidine phosphorylase inhibitor.
Definition
ChEBI: A hydrochloride obtained by combining tipiracil with one equivalent of hydrochloric acid. Used in combination with trifluridine, a nucleoside metabolic inhibitor, for treatment of advanced/relapsed unresectable colorectal cancer.
Biochem/physiol Actions
Tipiracil is an inhibitor of thymidine phosphorylase. Tipiracil is used in combination with trifluridine as TAS-102 for the treatment of refractory metastatic colorectal cancer. Tipiracil increases the bioavailability of trifluridine by blocking the enzyme that would otherwise protect the tumors by metabolizing trifluridine.
target
thymidine phosphorylase
References
1. tsukihara h1, nakagawa f2, sakamoto k et al. efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, tas-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts. oncol rep. 2015 may;33(5):2135-42. 2. dexter dl, wolberg wh, ansfield fj, helson l and heidelberger c: the clinical pharmacology of 5-trifluoro-methyl-2'-deoxyuridine. cancer res 32: 247-253, 1972.3. fukushima m, suzuki n, emura t et al. structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2'-deoxyribonucleosides. biochem pharmacol 59: 1227-1236, 2000.
TipiracilSupplier
- Tel
- 15502154572
- yuben012@sina.com
- Tel
- 0539-0539-8613587 17661611089
- 2639273505@qq.com
- Tel
- sales@boylechem.com
- Tel
- 400-6009262 16621234537
- chenyj@titansci.com
- Tel
- 21-21-56491756 13512199871
- sales@panhongchem.com
Tipiracil(183204-72-0)Related Product Information
- Tipiracil Impurity 2
- Tipiracil Impurity des Cl
- Tipiracil Impurity 5
- methyl 5-chloro-2,6-dioxo-3H-pyrimidine-4-carboxylate
- Tipiracil Impurity 4
- Tipiracil Impurity 2
- Tipiracil Impurity 1
- 6-(Chloromethyl)uracil
- 2-AMINO-1-PYRROLINE HYDROCHLORIDE
- 2,4(1H,3H)-Pyrimidinedione,5-chloro-6-(chloromethyl)-(9CI)
- tadalafi
- Levetiracetam
- Posaconazole